Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE. Beck D, et al. Among authors: buchner t. Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4. Leukemia. 2018. PMID: 28674423
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: buchner t. Leukemia. 2000 Feb;14(2):226-31. doi: 10.1038/sj.leu.2401668. Leukemia. 2000. PMID: 10673737
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
Müller-Tidow C, Metzelder SK, Buerger H, Packeisen J, Ganser A, Heil G, Kügler K, Adigüzel G, Schwäble J, Steffen B, Ludwig WD, Heinecke A, Büchner T, Berdel WE, Serve H. Müller-Tidow C, et al. Among authors: buchner t. Leukemia. 2004 Apr;18(4):720-6. doi: 10.1038/sj.leu.2403296. Leukemia. 2004. PMID: 14973498
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M. Köhnke T, et al. Among authors: buchner t. Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10. Leukemia. 2015. PMID: 24912430
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Büchner T, et al. Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. Leukemia. 2016. PMID: 26965440 Clinical Trial. No abstract available.
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Hiddemann W, Spiekermann K, Buske C, Feuring-Buske M, Braess J, Haferlach T, Schoch C, Kern W, Schnittger S, Berdel W, Wörmann B, Heinecke A, Sauerland C, Büchner T; German AML Cooperative Group. Hiddemann W, et al. Among authors: buchner t. Crit Rev Oncol Hematol. 2005 Nov;56(2):235-45. doi: 10.1016/j.critrevonc.2005.07.004. Epub 2005 Oct 3. Crit Rev Oncol Hematol. 2005. PMID: 16207531 Review.
395 results